BMX and Hypertension: All are preclinical; no clinical CV toxicity data (Liang et al., 2017; Liu F et al., 2013). Ibrutinib’s potent BMX inhibition raises the question of its contribution to ibrutinib’s hypertension/endothelial toxicity (Shirley, 2022).